---
document_datetime: 2025-10-23 09:44:15
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tuznue-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tuznue-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.5396595
conversion_datetime: 2025-12-19 21:25:36.025436
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tuznue

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 23/10/2025                          |                                             | SmPC                             |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                    |            |     |    | EMA/VR/0000301399   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|---------------------|
| Article 61(3) /                       | - Notification acc. Article 61(3) - Accepted Update of the package leaflet to introduce a list of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                     | 09/10/2025 |     | PL | EMA/N/0000303396    |
| Variation type IB / EMA/VR/0000287118 | B.I.c.1 Change in immediate packaging of the active substance - B.I.c.1.a Qualitative and/or quantitative composition - Accepted                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2025 | N/A |    |                     |
| Variation type IB / EMA/VR/0000272239 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.b Addition of a new in- process test and limits - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non- | 16/06/2025 | N/A |    |                     |

<div style=\"page-break-after: always\"></div>

|                                       | significant in-process test - Accepted                                                                                                                                                                                                                                                                                                                                                               |            |     |                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB /                   | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                                                                                  | 07/05/2025 | N/A | EMA/VR/0000261150 |
| Variation type IB / EMA/VR/0000264280 | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.b Addition of a new in- process test and limits - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.b Addition of a new in- process test and limits - Accepted | 05/05/2025 | N/A |                   |
| Variation type IB / EMA/VR/0000247419 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                        | 20/03/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

| Variation type IB /   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |      |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| EMA/VR/0000250711     | This was an application for a group of variations. B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted | 20/02/2025 | SmPC |